Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Discovery of Antibody Biomarker
share announcement

Discovery of Antibody Biomarker

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 December 2019) | Viewed by 7461

Special Issue Editor

Dr. Takaki Hiwasa

E-Mail Website
Guest Editor
Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
Interests: SEREX; immunome; cancer; atherosclerosis; cerebro- and cardiovascular disease; oncogene; protease; signal transduction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomarkers are important and indispensable not only for diagnosis but also for the identification of therapeutic targets. Thus far, many antigen, enzyme, and nucleic acid markers have been developed, yet only few antibody markers are known. Autoantibodies have causal roles in autoimmune diseases, and may affect the development of cancer. Until recently, it was believed that autoantibodies appeared only in patients with autoimmune disease or cancer. However, the recent development of technology has revealed that autoantibodies are developed against most proteins in the body. Such autoantibodies may reflect an individual’s medical history. Therefore, autoantibodies can be applicable for diagnosis of other varieties of diseases in addition to autoimmune disease and cancer. Antibody levels are tremendously increased by repeated exposure to antigens. Therefore, antibody markers are highly sensitive and capable of discriminate trivial alterations of cells and organs. It has been suggested that autoantibodies sometimes play causal roles in other diseases than autoimmune diseases. Thus, analysis of autoantibodies is effective in the identification of therapeutic targets. Remarkable development of antibody biomarkers is expected in the future.

This is the joint Special Issue both in IJMS and Diagnostics.

Dr. Takaki Hiwasa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoantibody biomarker
  • antibody technology
  • autoimmune disease
  • cancer immunology
  • neuroimmunology
  • diabetes mellitus
  • cardiovascular disease
  • atherosclerosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1010 KiB  
Article
Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea
by Yusuke Katsumata, Jiro Terada, Takuma Matsumura, Ken Koshikawa, Seiichiro Sakao, Go Tomiyoshi, Natsuko Shinmen, Rika Nakamura, Hideyuki Kuroda, Kengo Nagashima, Yoshio Kobayashi, Eiichi Kobayashi, Yasuo Iwadate, Xiao-Meng Zhang, Takaki Hiwasa and Koichiro Tatsumi
Diagnostics 2020, 10(2), 71; https://doi.org/10.3390/diagnostics10020071 - 27 Jan 2020
Cited by 8 | Viewed by 3041
Abstract
Biomarkers are not available for monitoring the onset and progression of coronary artery disease (CAD) in patients with obstructive sleep apnea (OSA), a major risk factor for arteriosclerotic cardiovascular diseases. This study aimed to test for correlation between circulating anti-Sorting Nexins 16 antibody [...] Read more.
Biomarkers are not available for monitoring the onset and progression of coronary artery disease (CAD) in patients with obstructive sleep apnea (OSA), a major risk factor for arteriosclerotic cardiovascular diseases. This study aimed to test for correlation between circulating anti-Sorting Nexins 16 antibody (SNX16-Ab) levels, CAD history and clinical parameters of patients with OSA. Sixty-four healthy donors, 82 adults with OSA, and 96 with acute coronary syndrome (ACS) were studied. Serum samples were collected at diagnostic polysomnography in the OSA group or at the disease onset in the ACS group. Serum SNX16-Ab levels were measured by amplified luminescence proximity homogeneous assay (AlphaLISA), and correlation between SNX16-Ab levels and clinical parameters was analyzed. SNX16-Ab levels and apnea-hypopnea index (AHI) were weakly correlated. Additionally, logistic regression analyses of OSA group identified that elevated SNX16-Ab level associated with the history of CAD. Circulating SNX16-Ab could increase during CAD pathogenesis in patients with OSA. Further prospective studies are required to prove the predictive potential of SNX16-Ab level in CAD onset of patients with OSA. Full article
(This article belongs to the Special Issue Discovery of Antibody Biomarker)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1282 KiB  
Review
Revisiting Cell Death Responses in Fibrotic Lung Disease: Crosstalk between Structured and Non-Structured Cells
by Kiyoharu Fukushima, Takashi Satoh, Hiroshi Kida and Atsushi Kumanogoh
Diagnostics 2020, 10(7), 504; https://doi.org/10.3390/diagnostics10070504 - 21 Jul 2020
Cited by 6 | Viewed by 4091
Abstract
Fibrosis is a life-threatening disorder caused by excessive formation of connective tissue that can affect several critical organs. Innate immune cells are involved in the development of various disorders, including lung fibrosis. To date, several hematopoietic cell types have been implicated in fibrosis, [...] Read more.
Fibrosis is a life-threatening disorder caused by excessive formation of connective tissue that can affect several critical organs. Innate immune cells are involved in the development of various disorders, including lung fibrosis. To date, several hematopoietic cell types have been implicated in fibrosis, including pro-fibrotic monocytes like fibrocytes and segregated-nucleus-containing atypical monocytes (SatMs), but the precise cellular and molecular mechanisms underlying its development remain unclear. Repetitive injury and subsequent cell death response are triggering events for lung fibrosis development. Crosstalk between lung structured and non-structured cells is known to regulate the key molecular event. We recently reported that RNA-binding motif protein 7 (RBM7) expression is highly upregulated in the fibrotic lung and plays fundamental roles in fibrosis development. RBM7 regulates nuclear degradation of NEAT1 non-coding RNA, resulting in sustained apoptosis in the lung epithelium and fibrosis. Apoptotic epithelial cells produce CXCL12, which leads to the recruitment of pro-fibrotic monocytes. Apoptosis is also the main source of autoantigens. Recent studies have revealed important functions for natural autoantibodies that react with specific sets of self-antigens and are unique to individual diseases. Here, we review recent insights into lung fibrosis development in association with crosstalk between structured cells like lung epithelial cells and non-structured cells like migrating immune cells, and discuss their relevance to acquired immunity through natural autoantibody production. Full article
(This article belongs to the Special Issue Discovery of Antibody Biomarker)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop